Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Immunodeficiency by defective expression of HLA class 1 is a very rare, primary, genetic, immunodeficiency disorder characterized by partial or complete absence of human leukocyte antigen class I expression resulting in a non-specific clinical picture of impaired immune response and susceptibility to infections.
Biomarker and diagnostic research for MHC class I deficiency has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for MHC class I deficiency.
10 publications have been identified in PubMed for MHC class I deficiency. Research spans Case Report / Case Series (50%), Review / Meta-Analysis (20%), and Diagnostic / Biomarker (10%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 5 | 50% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 1:59 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about MHC class I deficiency
2 |
20% |
Testing and diagnosis research | 1 | 10% |
Laboratory research | 1 | 10% |
Disease patterns and progression | 1 | 10% |
Bermejo-Olivera FJ (2026). [PMID: 41954665](https://pubmed.ncbi.nlm.nih.gov/41954665/). *J Clin Immunol*. [Case Report / Case Series]
Haskologlu S (2025). [PMID: 41126834](https://pubmed.ncbi.nlm.nih.gov/41126834/). *Front Immunol*. [Epidemiology / Natural History]
Luciani L (2025). [PMID: 41531537](https://pubmed.ncbi.nlm.nih.gov/41531537/). *J Hum Immun*. [Diagnostic / Biomarker]
Ponsford MJ (2025). [PMID: 41298860](https://pubmed.ncbi.nlm.nih.gov/41298860/). *J Clin Immunol*. [Case Report / Case Series]
Yamazawa S (2025). [PMID: 40278871](https://pubmed.ncbi.nlm.nih.gov/40278871/). *Virchows Arch*. [Basic Science / Preclinical]
Gadola SD (2025). [PMID: 42169988](https://pubmed.ncbi.nlm.nih.gov/42169988/). *J Hum Immun*. [Review / Meta-Analysis]
Zugazagoitia J (2024). [PMID: 38630789](https://pubmed.ncbi.nlm.nih.gov/38630789/). *Clin Cancer Res*. [Review / Meta-Analysis]
Samarkandy S (2024). [PMID: 39345282](https://pubmed.ncbi.nlm.nih.gov/39345282/). *JAAD Case Rep*. [Case Report / Case Series]
Elsayed A (2024). [PMID: 38866210](https://pubmed.ncbi.nlm.nih.gov/38866210/). *J Allergy Clin Immunol*. [Case Report / Case Series]
Ramalingam TR (2024). [PMID: 38989814](https://pubmed.ncbi.nlm.nih.gov/38989814/). *Pediatr Allergy Immunol*. [Case Report / Case Series]